Heme Onc Today New York Melanoma Meeting March 22-23, 2013 PD-1 antibodies
|
|
- Rolf McCarthy
- 6 years ago
- Views:
Transcription
1 Heme Onc Today New York Melanoma Meeting March 22-23, 2013 PD-1 antibodies Jeffrey Weber Moffitt Cancer Center Tampa, FL
2 Disclosures I have consulted for BMS, Merck, Genentech and GSK for Ad Boards and DSMBs I have received less than $10,000 per year from any of the above I have served in the past on a Speaker s Bureau for Genentech My institution has received research funding from BMS, Merck, Genentech and GSK
3 PD-1: Role in T Cell Activation What is PD-1? Member of CD28 family involved in T cell regulation Expressed by activated T cells, memory T cells, and regulatory T cells Downregulates T cell activity upon binding to PD-L1/L2 Tumor PD-L1 expression may correlate with negative prognosis potential mechanism of tumor self-defense PD-1 = programmed death-1. Curran MA et al. PNAS. 2010;107:
4 PD-1 is Important for Immune Tolerance PD-1 is an activation antigen expressed on T and B lymphocytes PD-1 interacts with its ligands (PD-L1 and PD-L2) to inhibit activation of T lymphocytes & anti-tumor immune response Human cancers can hijack the PD-1 pathway PD-1 blockade may reactivate antitumor immunity Hamid, O et al SMR 2012
5 Study Design: Phase 1/2 Multi-Dose Regimen 8-week treatment cycle Rapid PD or clinical deterioration Off study Day SCANS * * * * *Dose administered IV q2wk Unacceptable toxicity CR/PR/SD or PD but clinically stable Eligibility: Advanced MEL, RCC, NSCLC, CRC, or CRPC with PD after 1 to 5 systemic therapies Follow-up every 8 weeks x 6 (48 weeks) Treat to confirmed CR, worsening PD, unacceptable toxicity, or 12 cycles (96 weeks) MEL = malignant melanoma. Hodi FS et al. ASCO 2012 Annual Meeting. Abstract 8507.
6 BMS : Treatment-Related Adverse Events Drug-Related Adverse Event Total Population* All Grades Grades 3-4 MEL Total Population No. (%) of Patients, All Doses MEL Any adverse event 207 (70) 82 (79) 41 (14) 21 (20) Fatigue 72 (24) 30 (29) 5 (2) 2 (2) Rash 36 (12) 21 (20) Diarrhea 33 (11) 18 (17) 3 (1) 2 (2) Pruritus 28 (9) 15 (14) 1 (0.3) Nausea 24 (8) 9 (9) 1 (0.3) 1 (1) Appetite decreased 24 (8) 7 (7) Hemoglobin decreased 19 (6) 7 (7) 1 (0.3) 1 (1) Pyrexia 16 (5) 5 (5) *AEs occurring in 5% of the total population. Common grade 3-4 AEs also included lymphopenia (3 patients) and abdominal pain and lipase increased (2 each). An additional 27 grade 3-4-related AEs were observed and one or more occurred in a single patient. Hodi FS et al. ASCO 2012 Annual Meeting. Abstract 8507; Topalian S et al NEJM 2012
7 Pneumonitis in pt on PD-1 ab over time Dec 1, 2011 Oct 11, 2011 Jun 30, 2011
8 Clinical Activity of BMS in Melanoma Patients Pop Dose (mg/kg) Patients n ORR n (%) Duration of Response (mo) SD 24 weeks n (%) PFSR at 24 weeks (%) All MEL (31) 1.9+ to (6) (29) 5.6 to (7) (19) 1.9+ to (6) 31 MEL (30) 5.3+ to (11) (41) 9.2+ to (6) (20) 17.0 to ORR was assessed using modified RECIST v1.0. Three melanoma patients had a persistent reduction in baseline target lesions in the presence of new lesions but were not classified as responders for the ORR calculation. Hodi FS et al. ASCO 2012 Annual Meeting. Abstract 8507; Topalian S et al NEJM 2012
9 Changes in Target Lesions Over Time in Melanoma Patients after BMS Hodi, S. et al ASCO 2012
10 PD-L1 Expression in Melanoma PD-L1-positive metastatic lesions correlated with improved survival in 56 patients with stage III-IV melanoma 1 In patients with MEL, NSCLC, CRC, RCC, or CRPC treated with BMS (n = 42), PD-L1 expression in pretreatment tumor biopsies was associated with clinical outcomes, 17 IHC-negative biopsies with zero responses and 25 IHC-positive biopsies with 9 responses (36%) 2,3 Further studies in melanoma patients are planned to define the role of PD- L1 as a potential molecular marker of response to BMS Melanoma Immunohistochemical staining with anti-pd-l1 monoclonal antibody 5H1 of melanoma lymph node metastasis 4 1. Taube JM et al. Sci Transl Med. 2012;4:127ra37; 2. Topalian SL et al. ASCO 2012 Annual Meeting. Abstract 2509; 3. Hodi FS et al. ASCO 2012 Annual Meeting. Abstract 8507; 4. Topalian SL et al. N Engl J Med Jun 2 [Epub ahead of print].
11 Phase I Trial Of PD-1 Antibody BMS With Vaccine Patients were all HLA A*0201 positive and failed at least one prior regimen, but had not received ipilimumab 34 patients were treated at 1, 3 and 10 mg/kg PD-1 antibody every 2 weeks for 12 weeks with a multi-peptide vaccine Up to two cycles given for 24 weeks, then patients that were stable or better were boosted every 12 weeks for up to 2 years Peptides included gp (210M), gp (288V), NY ESO (165V), and MART (27L) all emulsiified in Montanide ISA 51VG Leukapheresis done at week 0, 12 and 24 for T cell assays New cohorts include those who are HLA A2 positive and had either no, or dose limiting prior ipi toxicity, or are A2 negative and had no ipi dose limiting iraes From Kudchadkar, R et al ASCO 2012
12 Demographics of patients receiving PD-1 antibody with a peptide vaccine Characteristic Sex Male Female Ethnicity Not Hispanic or Latino Hispanic or Latino Age Median (range), years <65 years 65 years BRAF mutational status Non-mutated Mutated Unknown Metastatic (M) classification at diagnosis M1a M1b M1c Serum LDH No data Normal (<250 U/L) Elevated Origin of melanoma Cutaneous Ocular Unknown Primary N (16-87) From Kudchadkar, R et al ASCO 2012
13 Toxicities of PD-1 antibody with vaccine Adverse event Number of Patients, n (%) 1 mg/kg (n = 10) 3 mg/kg (n = 13) 10 mg/kg (n = 11) Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4 Fatique 7 (70%) (42%) 2 (17%) (67%) Injection site reaction 4 (40%) 1 (10%) (50%) 2 (17%) (42%) 1 (8%) 0 0 Fever 3 (30%) (8%) 1 (8%) (8%) Chills 1 (10%) (8%) (17%) Infusion reaction (8%) Rash 3 (30%) (8%) 1 (8%) (33%) Pruritis 2 (20%) Diarrhea 5 (50%) (25%) 1 (8%) (17%) Nausea 4 (40%) (33%) 1 (8%) (8%) Dyspnea 1 (10%) (8%) 1 (8%) (8%) Pneumonitis (8%) 0 1 (8%) Arthralgia 0 1 (10%) (8%) Thyroiditis (8%) (8%) Eye pain 1 (10%) (8%) From Kudchadkar, R et al ASCO 2012
14 From Kudchadkar, R et al ASCO 2012 Clinical efficacy of PD-1 antibody with a peptide vaccine 1 CR and 8 PR of 34 patients evaluated for response 3 patients were stable for 24 weeks ORR = 28% with DCR (CR+PR+SD) = 35% The drug was well tolerated for up to 84 weeks, with no MTD reached; one episode of grade three optic neuritis and one grade three pulmonary toxicity observed, one DLT at 3 mg/kg Thyroiditis, hypophysitis, fatigue, pulmonary toxicity, rash and fevers observed
15 PR CR SD PD Days on study From Kudchadkar, R et al ASCO 2012
16 Box Plot: Pre-treatment NY-ESO-1( V) tetramer positive CD8 T cells Percentage (%) 3 P= NY-ESO Responders Non-Responders From Kudchadkar, R et al ASCO 2012
17 Changes in T reg and CTLA-4 expressing cells are associated with response with BMS Decreased T regs and response p=0.001 Decreased CTLA-4/CD8 T cells and response p=0.01 From Kudchadkar R et al ASCO 2012
18 Regression With Ipilimumab After Failing Anti-PD-1 Ab Pretreatment Postcycle 1 ipilimumab From Kudchadkar R et al ASCO 2012
19 %-PD-1 on CD4+ T cells %-PD-1 on CD4+ T cells Changes in PD-1 on CD4 T cells induced by ipilimumab at 3 and 6 months PD-1 induction by ipilimumab treatment on CD4+ T cells 40 P= P< pre 3-mon 0 pre N=22 N=33 6-mon Weber, J et al unpublished data 2013
20 CT scans pre- and 12 weeks post PD-1 ab after failing TIL and ipilimumab Pre-treatment Post-treatment week 12
21 Re-induction therapy with anti-pd-1 antibody: similar kinetics to ipilimumab? Lipson, E et al CCR 2012
22 Future Plans: BMS Phase II trial of simultaneous PD-1 ab and ipilimumab Phase II trial of sequential reciprocal PD-1 ab and ipilimumab Phase III 2:1 randomized second line trial of PD-1 ab at 3 mg/kg versus investigator s choice chemotherapy Pivotal phase III randomized first line trial of PD-1 ab at 3 mg/kg versus dacarbazine (ex-us) Pivotal phase III randomized first line trial of PD-1 ab at 3 mg/kg versus ipilimumab versus the combination
23 MK-3475 is a High-Affinity Humanized IgG4 PD-1 Blocking Antibody Mouse variable (CDR) sequences grafted onto human framework Parental Antibody Mouse IgG1 K D : ~28 pm IC50: ~800 pm EC50: ~118 pm MK-3475 Human IgG4 K D : ~29 pm IC50: ~600 pm EC50: ~70 pm Similar reactivity to human and cynomolgus PD-1, no reactivity to mouse or rat PD-1 Humanized IgG4 - no cytotoxic (ADCC/CDC) activity Contains stabilizing S228P sequence alteration Hamid, O et al SMR 2012
24 Phase I PD-1 Antibody MK-3475 Cohorts of 3-6 patients were enrolled (3+3 design) at escalating IV doses of 1, 3, and 10 mg/kg IgG4 human MoAb Nine patients, 3 at each dose level, completed the dose-limiting toxicity (DLT) period (28 d). Patients had non small cell lung cancer (NSCLC, n=3), rectal cancer (n=2), melanoma (MEL, n=2), sarcoma (n=1), or carcinoid (n=1). Drug-related adverse events (AEs) included Grade 1 fatigue (n=3), nausea (n=2), diarrhea (n=1), dysgeusia (n=1), breast pain (n=1), and pruritus (n=1). One drug-related Grade 2 AE of pruritus was reported. No drug-related AEs Grade 3 seen Updated melanoma data show 10 pts treated, one ucr, 3 uprs, 2 SD, an excellent record At 10 mg/kg, half life of the antibody was 13.6 days Patnaik, J et al ASCO 2012
25 Patient Characteristics Part B Total Enrollment: Dec, 2011 through July, 2012 Median Age Male Female ECOG PS 0 PS 1 Unknown 10.0 mg/kg every 2 week (FPI: Dec, 2011) 10.0 mg/kg every 3 week (FPI: Jan, 2012) 2.0 mg/kg every 3 week (FPI: May, 2012) B-raf mutation status Yes No Unknown Prior therapy with IPI Prior therapy with B-raf or/and MEK inhibitors N= 132 N=57 (43.2%) N=54 (40.9%) N=21 (15.9%) 63.0 yrs-old N=77 (58.3%) N=55 (41.6%) N=93 (70.4%) N=36 (27.3%) N=3 (2.3%) N=26 (19.7%) N=88 (66.7%) N=18 (13.6%) N=48 (36.3%) N=4 (3.0%) Hamid, O et al SMR 2012 FPI = First Patient In (dosed)
26 Immune-Related Adverse Events per Investigator Assessment; Overall Incidence 2 Patients Part B: All Melanoma Patients: N=132 Adverse Events All Grades Grades 3-5 All AEs All AEs N (%) N (%) Any Immune Adverse Event 21 (15.9) 7 (5.3%) Rash 6 (4.5%) 0 Influenza 4 (3.0%) 0 Pruritus 3 (2.2%) 0 Eczema 3 (2.2%) 0 Vitiligo 3 (2.2%) 0 Hypothyroidism 3 (2.2%) 1 (0.7%) Pyrexia 2 (1.5%) 0 Arthralgia 2 (1.5%) 0 Myositis 2 (1.5%) 0 Cough 2 (1.5%) 0 Hamid, O et al SMR 2012 Patients who started treatment with MK-3475 before July 31, 2012 and have entered data by Sept 28, 2012
27 Best Overall Response of MK-3475 (Unconfirmed + Confirmed Responses) in Advanced MEL Patients (Part B; based on immune related Response Criteria*) Complete Response (N, 95% CI) Objective Response (N, 95% CI) Disease Control Rate (N, 95% CI) All MEL N=85 9% (8; 4% -18%) 51% (43; 39 % -61%) 59% (50; 48% -69%) IPI Naïve N=58 14% (8; 6% -25%) 55% (32; 41% -68%) 64% (37; 50% -76%) IPI Treated N=27 0% (0) 41% (11; 22% -61%) 48% (13; 29% -68%) All patients were dosed at 10 mg/kg Includes all patients who received first dose as of April 25, Investigator reported response information as of October 19, Objective response= confirmed and unconfirmed complete and partial response Disease control rate= Objective response + stable disease *irrc: Wolchok, JD, Hoos, A, O Day S, et al., Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune- Related Response Criteria. Clinical Cancer Research, 2009 Dec 1;15(23): Epub 2009 Nov 24) Hamid, O et al SMR 2012
28 % Change from Baseline (sum of longest diameters) Maximum Percent Change from Baseline in Tumor Burden by irrc (Central Review Part B) * Hamid, O et al SMR 2012 Individual Patient ** *0 % change in tumor burden **Skin only disease (n=1) with complete regression All patients are dosed at 10mg/kg
29 Characteristics of Responses: Time to Respond & Duration for 43 Patients with Objective Response Hamid, O et al SMR 2012 IPI naive IPI treated Complete Response Partial Response On Study Median duration of treatment, 7.6 months (3.3-11) one patients discontinued due to PD and four patients discontinued due to AEs On Treatment Duration in Weeks
30 Future plans: Randomized phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma (P08719/MK ) R A N D O M I Z A T I O N 1:1:1 MK-3475 at 2 mg/kg MK-3475 at 10 mg/kg Chemotherapy treatment of Investigator choice PD Crossover Eligibility MK-3475 Main objective To evaluate clinical efficacy (ORR, PFS, and OS) in patients with previously treated advanced melanoma receiving either MK-3475 or chemotherapy Hamid, O et al SMR 2012
31 Conclusions BMS with vaccine at 1, 3 or 10 mg/kg has a 28% RECIST ORR in previously treated, ipilimumab naïve melanoma, and 31% ORR at 0.3 to 10 mg/kg; 3 mg/kg had the best efficacy Only one DLT of 34 patients observed in the 12 week DLT period in the Moffitt trial: optic neuritis, two other patients had grade 3 pneumonitis between 12 and 24 weeks MK-3475 has a 30-50% ORR by irrc in ipi naïve or experienced patients Both are generally well tolerated, with excellent duration of response Increased CD4/CD8+ CTLA-4+ T cells and increased T regulatory cells found in non-responders to BMS with vaccine These biomarker data support sequencing trials of PD-1 antibodies and ipilimumab and suggest predictive markers to be evaluated
32 Acknowledgements MacLean Hall Jay Martinez Bin Yu Wenshi Wang Amod Sarnaik Donna Gallenstein Patricia Urbas Ragini Kudchadkar Geoffrey Gibney Nursing staff Clinic 5 Tissue Core Acquisition Jodi Kroeger Kate Shapland Shari Pilon-Thomas James Mulé Vernon Sondak Jonathan Zager Ricardo Gonzalez National Cancer Institute Donald A. Adam Comprehensive Melanoma Research Center grant
Clinical Activity and Safety of Anti-PD-1 (BMS , MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer
Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer J.R. Brahmer, 1 L. Horn, 2 S.J. Antonia, 3 D. Spigel, 4 L. Gandhi, 5 L.V. Sequist,
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationImproving Immunotherapy for Melanoma
Improving Immunotherapy for Melanoma David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/ Harvard Cancer Center Harvard Medical School Immunotherapy Improvement Model All patients All
More informationPresenter Disclosure Information
Presenter Disclosure Information Tara C. Gangadhar, M.D. The following relationships exist related to this presentation: Research funding (Institution): Incyte Corporation and Merck & Co., Inc Preliminary
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationCheckpoint-Inhibitoren beim Lungenkarzinom. Dr. Helge Bischoff Thoraxklinik Heidelberg
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationPhase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma
Phase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma Abstract #3003 Ribas A, Butler M, Lutzky J, Lawrence D, Robert C, Miller W,
More information2019 ASCO-SITC. Nektar Therapeutics Investor & Analyst Call. March 1, 2019
Nektar Therapeutics Investor & Analyst Call March 1, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Antitumor Activity and Safety of FPA144, an ADCCenhanced, FGFR2b Isoform-Selective Monoclonal Antibody, in Patients with FGFR2b + Gastric Cancer and Advanced Solid Tumors Jeeyun Lee 1, Johanna Bendell
More informationClinicalTrials.gov Identifier: NCT Adi Diab 1, Nizar Tannir 1, Daniel Cho
Pivot-02: Preliminary safety, efficacy and biomarker results from dose escalation of the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic melanoma,
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationInterleukin-2 Single Agent and Combinations
Interleukin-2 Single Agent and Combinations Michael K Wong MD PhD Norris Cancer Center University of Southern California mike.wong@med.usc.edu Disclosures Advisory Board Attendance Merck Bristol Myers
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationMind the Gap : Challenges in First-in- Man Evaluation of Immuno-Oncology Drugs
Mind the Gap : Challenges in First-in- Man Evaluation of Immuno-Oncology Drugs Ignacio Garcia-Ribas MD, PhD Senior Medical Director Early Clinical Research & Development, Oncology Therapeutic Area Takeda
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationResponse and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationJefferies 2018 Healthcare Conference. June 6, 2018
Jefferies 2018 Healthcare Conference z June 6, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of ongoing
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationpresentation session & clinical Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania
Melanoma: highlights from the oral presentation session & clinical science symposium at ASCO 2009 Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania Abstracts to be discussed
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationToxicity from Checkpoint Inhibitors. James Larkin FRCP PhD
Toxicity from Checkpoint Inhibitors James Larkin FRCP PhD Disclosures Research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): BMS, Eisai, GSK, MSD, Novartis, Pfizer, Roche/Genentech
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationApproaches To Treating Advanced Melanoma
Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures
More informationNewest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management
Newest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management Stacey Jassey Megan Brafford David Kwasny This CE activity was originally presented live at the 2015 NASP Annual Meeting
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationCTLA4 Blockade in Melanoma Treatment. Antoni Ribas, M.D. Associate Professor of Medicine and Surgery University of California Los Angeles.
CTLA Blockade in Melanoma Treatment Antoni Ribas, M.D. Associate Professor of Medicine and Surgery University of California Los Angeles. CTLA Negatively Modulates T-Cell Activation MHC Antigen TCR Dendritic
More informationCancer Progress. The State of Play in Immuno-Oncology
Cancer Progress The State of Play in Immuno-Oncology Axel Hoos, MD, PhD VP, Oncology R&D, Glaxo Smith Kline Co-Director, Cancer Immunotherapy Consortium Key Drivers in Immuno-Oncology Science Methods Combinations
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationOne Moment Please. Skin Cancer. Today s Webcast Friday, 09/09/11, Noon. David Carr, MD
One Moment Please One Moment Please Skin Cancer Thomas Olencki, DO David Carr, MD Today s Webcast Friday, 09/09/11, Noon 1 New Features Enlarge Slides Links Chapters Polling Use the email function to let
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced Melanoma
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced Melanoma This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationgp100 (209-2M) peptide and High Dose Interleukin-2 in HLA-A2+ Advanced Melanoma Patients Cytokine Working Group Experience
gp100 (209-2M) peptide and High Dose Interleukin-2 in HLA-A2+ Advanced Melanoma Patients Cytokine Working Group Experience Metastatic Melanoma- Progress in Past 30 years Approved Therapies (USA) Date DTIC
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX /- nivolumab (nivo) in patients with advanced cancers
ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-211 +/- nivolumab (nivo) in patients with advanced cancers Timothy A. Yap 1, Howard A. Burris 2, Shivaani Kummar 3, Gerald
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationPhase 1b KEYNOTE-200 (STORM):
Phase 1b KEYNOTE-2 (STORM): A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients Hardev S. Pandha 1, Kevin J. Harrington
More informationEnlarge Slides. One Moment Please. Skin Cancer. Thomas Olencki, DO David Carr, MD. Today s Webcast Friday, 09/09/11, Noon
New Features Enlarge Slides Links One Moment Please Chapters Polling Use the email function to let us know what you think One Moment Please Skin Cancer Thomas Olencki, DO David Carr, MD Today s Webcast
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationA Phase 2 Study of Glembatumumab Vedotin, an Antibody Drug Conjugate Targeting gpnmb, in Advanced Melanoma
A Phase 2 Study of Glembatumumab Vedotin, an Antibody Drug Conjugate Targeting gpnmb, in Advanced Melanoma Patrick A. Ott, MD, PhD 1, Anna C. Pavlick, DO 2, Douglas B. Johnson, MD 3, Lowell Hart, MD 4,
More informationMelanoma- Fighting the Dark Side
Melanoma- Fighting the Dark Side Anna C. Pavlick, BSN, MSc, DO, MBA Professor of Medicine and Dermatology Director, NYU Melanoma Program Director, NYU Clinical Trials Office NYU Perlmutter Cancer Center
More informationEndogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade
Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Jedd Wolchok Ludwig Center for Cancer Immunotherapy Memorial Sloan-Kettering Cancer Center MEMORIAL SLOAN- KETTERING
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationEmerging Trends & Strategies in the Treatment & Management of Metastatic Melanoma. Evan J. Lipson, MD
Emerging Trends & Strategies in the Treatment & Management of Metastatic Melanoma Evan J. Lipson, MD Johns Hopkins University School of Medicine Sidney Kimmel Comprehensive Cancer Center April 25, 2014
More informationWe re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications
We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications Adam Peele, PharmD, BCPS, BCOP Oncology Pharmacy Manager Cone Health Disclosures Merck Pharmaceuticals Speaker s Bureau 1 Objectives
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationMelanoma in Focus: Update on Novel Therapy, Emerging Agents, and Optimizing Patient Care Presentation 1
Presentation 1 The following is a transcript from a web-based CME -certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More information9/22/2016. Introduction / Goals. What is Cancer? Pharmacologic Strategies to Treat Cancer. Immune System Modulation
Immunomodulatory Therapies in Cancer Treatment Bill O Hara, PharmD, BCPS, BCOP Advanced Practice Pharmacist, Oncology/BMT Thomas Jefferson University Hospital Introduction / Goals What is Cancer? How can
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationOptimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma
Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
More informationIdera Pharmaceuticals. ASCO 2018 Annual Meeting Investor/Analyst Event
Idera Pharmaceuticals ASCO 2018 Annual Meeting Investor/Analyst Event Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning of
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationBreast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
More informationMarshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011
Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011 Most common form of cancer in adults ages 25-29 3-5% of skin cancers but 65-75% of deaths Most common metastasis to small
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More information